Filling the data gap on CGRP mAb therapy in low- to middle-income countries in Southeast Asia: insights from a real-world study in Thailand
The first real-world study in Thailand demonstrated that CGRP mAbs therapy had efficacy for migraine treatment, as evidenced by a reduction in MHDs, decreased disability, and reduced use of abortive medications. Additionally, the response pattern to CGRP mAbs therapy was similar between EM and CM in terms of MHDs reduction and MIDAS score improvement.
Authors
- Akarin Hiransuthikul (ORCID: https://orcid.org/0000-0003-1906-8171)
- Thanakit Pongpitakmetha (ORCID: https://orcid.org/0000-0002-8338-4649)
- Wanakorn Rattanawong (ORCID: https://orcid.org/0000-0001-7277-9699)
- Prakit Anukoolwittaya (ORCID: https://orcid.org/0000-0001-9440-1996)
- Sekh Thanprasertsuk (ORCID: https://orcid.org/0000-0002-0267-1372)
Institutions
- Thai Red Cross Society (TH)
- Chulalongkorn University (TH)
- King Chulalongkorn Memorial Hospital (TH)
- King Mongkut's Institute of Technology Ladkrabang (TH)
Publication Details
- Journal
- The Journal of Headache and Pain
- Published
- 2024-09-12
- DOI
- https://doi.org/10.1186/s10194-024-01859-3
- Citations
- 7
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.70